Shares of Pfizer Inc. PFE dropped 0.81% to $29.42 Friday, on what proved to be an all-around mixed trading session for the ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Shares of Pfizer Inc. PFE shed 0.27% to $29.75 Wednesday, on what proved to be an all-around dismal trading session for the ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...